Oral HPV rarely persisted across four Nigerian cohort visits, but HIV shifted the clearance pattern
Oral human papillomavirus emerged at least once in a meaningful minority of Nigerian mothers and youth, yet the infection usually did not linger. Across the prospective HOMINY cohort, 1075 participants were followed through four visits spaced 6 months apart, and 112 people had oral HPV detected at least once. The overall detection rate was 10.4%, with 11.1% among mothers and 10% among youth, numbers that place oral exposure squarely in the range of a common but often fleeting mucosal infection rather than a uniformly sustained one.
The study becomes more clinically interesting where detection gives way to durability. Persistence was uncommon at 1.9%, and only three participants had oral HPV DNA detected at all four visits. Clearance dominated every interval, suggesting that many oral infections either never established durable mucosal residence or were rapidly contained by local host defenses. In a setting where HPV-associated oropharyngeal cancer is rising, that brief biological window matters, because persistent infection is the substrate from which malignant transformation can eventually develop.
Persistence clustered in people with HIV while acquisition stayed similar
The clearest divergence appeared not in acquisition, but in clearance. Markov multistate models showed slower clearance in people living with HIV, with a hazard ratio of 0.42 and a 95% confidence interval of 0.22 to 0.77. Acquisition did not differ materially by HIV status, with a hazard ratio of 0.77 and a 95% confidence interval of 0.39 to 1.5. In practical terms, HIV did not seem to make oral HPV more likely to appear during follow-up; it made the virus harder to eliminate once it was present.
That pattern fits mucosal immunology. Persistent HPV depends less on a single exposure than on the host’s ability to restore epithelial control, recruit effective cell-mediated immunity, and clear infected basal cells before they seed a stable reservoir. HIV can weaken those defenses in ways that do not necessarily increase the rate of new detection at every time point, yet still prolong the time an infection remains detectable. The result is a smaller but more consequential pool of persistent infection among people with HIV, and this cohort found exactly that distribution.
A short infection can still be clinically important when the host cannot clear it efficiently.
Vaccine coverage reached only a fraction of ever-positive participants
Genotype distribution raised another concern. Only 31.2% of participants who were ever positive carried a Gardasil-9 preventable strain of HPV, leaving most detected infections outside current vaccine coverage. HPV16 and HPV39 were the most frequent genotypes in the cohort. HPV16 is the genotype most strongly linked to HPV-driven oropharyngeal malignancy, while HPV39 is not covered by Gardasil-9 and falls into the broader category of oncogenic types that current vaccination cannot directly prevent.
This matters because public health messaging often treats vaccination as if it were a complete firewall against all oral HPV-related risk. The data here argue for a narrower claim. Vaccination remains crucial, but a substantial share of oral HPV detected in this Nigerian cohort involved types that current formulations do not target, especially among the infections that persisted. In other words, the vaccine-preventable fraction was real but limited, and the non-vaccine burden was not trivial.
Mother-youth concordance suggests shared circulation inside households or close networks
The cohort also produced a biologically plausible signal of intrafamilial or close-contact transmission. Mother-youth genotype concordance exceeded chance, with permutation testing yielding p=0.009. The analysis does not prove direct transmission in individual pairs, but it does show that matching genotype patterns occurred more often than expected randomly. In a mother-youth cohort, that finding points toward shared exposure patterns, close household contact, or other common social and behavioral pathways that permit oral HPV circulation within family networks.
This is where the study reaches beyond a simple prevalence estimate. Oral HPV in this setting is not just an isolated individual infection event; it appears embedded in a population structure shaped by age, caregiving contact, and HIV-related immune status. Concordance between mothers and youth reinforces the idea that prevention cannot rely on a single clinical encounter. It has to account for household transmission dynamics, sexual health education, and vaccine access across the life course.
What the four-visit design adds, and what it cannot settle
The prospective design strengthens the report by moving past one-time detection. Four visits at 6-month intervals allowed the investigators to distinguish incident detection from persistence and clearance, which is essential for interpreting oral HPV biology. The use of oral rinses and genotyping with the Seegene Allplex HPV28 assay also provided type-level resolution across 28 genotypes, enabling a more realistic view of vaccine coverage and non-vaccine burden.
Several details still limit how far the findings can be carried into practice. The report is a preprint and has not undergone peer review. The summary available here does not provide lesion-level outcomes, oropharyngeal cancer incidence, sexual behavior data, antiretroviral treatment metrics, or immune markers that would help explain why persistence was concentrated in people with HIV. The cohort was also specific to Nigerian mothers and youth, so generalizability to other regions, age groups, and transmission settings remains uncertain.
Even with those limits, the biological signal is hard to ignore. Oral HPV in this cohort was common enough to matter, but usually transient; when it persisted, HIV status shaped the clearance curve, and the persistent infections were often outside current vaccine coverage. The next step is not just broader surveillance, but studies that connect oral genotype persistence to oral immune function, antiretroviral control, and eventual cancer precursors in sub-Saharan African populations.